Genelux Advances Olvi-Vec Trials in Lung and Ovarian Cancer, Anticipates Key Data Readouts
Genelux is actively enrolling patients in a Phase 3 trial for platinum-resistant/refractory ovarian cancer, with topline results expected in the latter half of 2025.
Genelux Doses First Patient in Phase 2 Trial of Olvi-Vec for Recurrent NSCLC
Genelux has dosed the first patient in a Phase 2 clinical trial (VIRO-25) evaluating Olvi-Vec for recurrent non-small cell lung cancer (NSCLC).